IPA Ushers in New Leadership to Drive Future Growth

By
CID Editorial Team
-
ipa-ushers-in-new-leadership-to-drive-future-growth

The Indian Pharmaceutical Alliance (IPA) announced a major leadership transition, marking the beginning of a new chapter for the industry’s apex body. Dr. Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, will lead as President. He succeeds Samir Mehta, Chairman of Torrent Group, who successfully guided the association in advancing its mission. Glenn Saldanha, Chairman and Managing Director of Glenmark, joins the leadership team as Vice President.

Leadership Change at a Transformative Moment for Indian Pharma
The leadership transition comes at a pivotal time for the Indian pharmaceutical industry. Recent GST reforms have laid the foundation for a more affordable, accessible, and patient-centric healthcare ecosystem. Simultaneously, India is strengthening its position as a global hub for specialty medicines, biosimilars, and cutting-edge therapies. With this dynamic backdrop, the new IPA leadership aims to accelerate growth, foster innovation, and enhance India’s contribution to global healthcare. Their focus will be on building on the industry’s core strengths and advancing its leadership in research, innovation, and quality.

Outgoing President Highlights Industry’s Strengthened Global Role

Samir Mehta, Chairman of Torrent Group and Immediate Past President of IPA, said, “It has been a privilege to serve as President of IPA and work alongside an exceptional team of leaders committed to advancing India’s pharmaceutical sector. Together, we strengthened the industry’s voice and reinforced its role in delivering affordable and innovative healthcare solutions globally. I am confident that under the new leadership team, IPA will continue to shape the future of global healthcare.”

Dr. Sharvil Patel Outlines Vision for a Self-Reliant India

Dr. Sharvil Patel expressed, “I am honoured to take on this role and thank Mr. Samir Mehta for his outstanding stewardship in strengthening IPA’s voice and impact. Building on this foundation, breakthroughs at Zydus — such as India’s first NCE, our foray into MedTech and the global CDMO business, and our advances in vaccines and biologics — inspire my vision to build a strong, self-reliant India”.

Focus on Innovation and Global Partnerships

Glenn Saldanha, Chairman and Managing Director of Glenmark and the new Vice President of IPA, emphasized, “I am delighted to join the IPA leadership team and contribute to shaping the industry’s next chapter.

Our recent global partnership with AbbVie highlights how Indian pharma is moving up the innovation curve. Together, we will strengthen India’s leadership in delivering high-quality, affordable, and future-ready healthcare solutions.”

IPA to Build on Reforms and Accelerate Access

Sudarshan Jain, Secretary General of IPA, reaffirmed, “The Indian pharmaceutical industry has been playing a vital role in advancing the industry’s vision for patient care and access. With the new leadership team, we will continue to build on recent reforms and breakthroughs. Our focus will be on innovation, patient access, and maintaining the highest standards of quality in healthcare.”

A New Era for India’s Pharma Industry

The Indian pharmaceutical sector is entering a new growth phase. The IPA’s refreshed leadership will strengthen India’s global role in healthcare innovation. They will also drive patient-focused reforms and advance the nation’s vision of becoming a self-reliant, innovation-led pharma powerhouse. According to the IPA press release, the Indian Pharmaceutical Alliance is building on its strong legacy and bold roadmap. It will play an even more influential role in shaping the future of healthcare in India and globally.